225 related articles for article (PubMed ID: 22386745)
1. Economic evaluation of vaccination programme of 7-valent pneumococcal conjugate vaccine to the birth cohort in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2012 May; 30(22):3320-8. PubMed ID: 22386745
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2013 Jun; 31(25):2762-71. PubMed ID: 23588088
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
[TBL] [Abstract][Full Text] [Related]
5. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
Hoshi SL; Kondo M; Okubo I
PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of vaccination programme of mumps vaccine to the birth cohort in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2014 Jul; 32(33):4189-97. PubMed ID: 24923640
[TBL] [Abstract][Full Text] [Related]
7. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina.
Urueña A; Pippo T; Betelu MS; Virgilio F; Giglio N; Gentile A; Jimenez SG; Jáuregui B; Clark AD; Diosque M; Vizzotti C
Vaccine; 2011 Jul; 29(31):4963-72. PubMed ID: 21621575
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina.
Giglio ND; Cane AD; Micone P; Gentile A
Vaccine; 2010 Mar; 28(11):2302-10. PubMed ID: 20064478
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children.
Castañeda-Orjuela C; Alvis-Guzmán N; Velandia-González M; De la Hoz-Restrepo F
Vaccine; 2012 Mar; 30(11):1936-43. PubMed ID: 22266291
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
[TBL] [Abstract][Full Text] [Related]
16. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.
Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M
Value Health; 2004; 7(1):36-51. PubMed ID: 14720129
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).
Díez-Domingo J; Ridao-López M; Gutiérrez-Gimeno MV; Puig-Barberá J; Lluch-Rodrigo JA; Pastor-Villalba E
Vaccine; 2011 Dec; 29(52):9640-8. PubMed ID: 22027484
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay.
Kieninger MP; Caballero EG; Sosa AA; Amarilla CT; Jáuregui B; Janusz CB; Clark AD; Castellanos RM
Vaccine; 2015 May; 33 Suppl 1():A143-53. PubMed ID: 25919155
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.
Mo X; Gai Tobe R; Liu X; Mori R
Pediatr Infect Dis J; 2016 Nov; 35(11):e353-e361. PubMed ID: 27753771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]